Startseite
 
 
  NEW ON THE MARKET
 

Oral factor Xa inhibitor rivaroxaban (XARELTO) for prophylaxis of thromboembolism

 
  THERAPY FROM A CRITICAL VIEWPOINT
 

Anticholinergic drug tiotropium (SPIRIVA) for COLD - results from UPLIFT- study

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Oral human rotavirus vaccine: what is the benefit of ROTARIX and ROTATEQ?
Early diagnosis of diseases: is screening with the DIAPAT-Health-check reasonable?

 
  IN BRIEF
 

Do not presribe: oral hypoglycemic agent rosiglitazone (AVANDIA)

St John's wort (e.g. JARSIN): effective as antidepressant only in German speaking countries?

 
  CURRENT ADR NETWORK REPORT
 

Toxic epidermal necrolysis due to COX-2-inhibitor etoricoxib (ARCOXIA)

 
  SIDE EFFECTS
 

Finally: cannabinoid receptor antagonist rimonabant (ACOMPLIA) off market

 
© arznei-telegramm 11/2008